What corporate insiders disclosed

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Sale of shares pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 16, 2026.

F2: Reflects the weighted average price as the shares were sold in multiple transactions. The per share transaction price ranged from $252.02 to $252.78. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Reflects the weighted average price as the shares were sold in multiple transactions. The per share transaction price ranged from $253.08 to $253.14. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Sale of shares pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 16, 2026.

F2: Reflects the weighted average price as the shares were sold in multiple transactions. The per share transaction price ranged from $252.02 to $252.78. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Reflects the weighted average price as the shares were sold in multiple transactions. The per share transaction price ranged from $253.08 to $253.14. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.

F2: Each Restricted Stock Unit is the economic equivalent of one share of Qualcomm common stock and converts on a one-for-one basis.

F3: These Restricted Stock Units (and allocable dividend equivalents) vest in equal one-third amounts on October 15, 2025, 2026 and 2027.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into in good faith by the Reporting Person on April 7, 2026 for investment diversification purposes.

F2: Includes 6,442.63 restricted stock units which are subject to certain vesting and forfeiture provisions.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: The shares of Common Stock were acquired pursuant to the Kingsway America Inc. Employee Share Purchase Plan, as amended and restated effective May 29, 2014 (the "ESPP"). Pursuant to the ESPP, eligible employees may contribute an amount up to 5% of adjusted salary for each regular payroll period and, to the extent such employee has been employed by Kingsway America Inc. and its subsidiaries for 12 months, the company will make a matching contribution equal to 100% of such employee's contribution. The employee contributions and company contributions are used to purchase, as soon as administratively practicable after the date of such contributions, shares of Kingsway Corporation The shares are acquired by the administrator of the ESPP on the open market through the services of a duly registered stockbroker.

F2: Includes 6,909 shares of restricted stock granted on December 4, 2024, and 14,568 shares of restricted stock granted on March 17, 2026.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The sale reported herein represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.

F3: The RSUs vest in three equal annual installments beginning on October 15, 2026.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.23 to $23.84, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.66 to $24.56, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: The transactions reported herein were open market purchases of Common Stock effected on October 16, 2026.

price qualified by unrecognized footnote

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Each restricted stock unit represents a contingent right to receive without payment one share of common stock of the Issuer.

F2: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the issuance of shares related to the restricted stock units that vested on October 15, 2026. The "sell to cover" transactions were effected pursuant to a Rule 10b5-1 trading plan and do not represent discretionary trades by the Reporting Person.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.89 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

F4: On September 29, 2025, the Reporting Person was granted 200,000 restricted stock units that vest in 12 equal quarterly increments commencing on July 15, 2025, with the first quarterly vesting occurring on October 15, 2025.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Each restricted stock unit represents a contingent right to receive without payment one share of common stock of the Issuer.

F2: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the issuance of shares related to the restricted stock units that vested on October 15, 2026. The "sell to cover" transactions were effected pursuant to a Rule 10b5-1 trading plan and do not represent discretionary trades by the Reporting Person.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.89 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

F4: On September 29, 2025, the Reporting Person was granted 100,000 restricted stock units that vest in 12 equal quarterly increments, with the first quarterly increment vesting on October 15, 2025.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.

F2: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.98. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.

F3: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.95. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.

F4: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.89 to $1.90. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.

F5: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: The purchases reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 15 June 2026.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and assumed by Clear Street LLC, providing for the sale of shares of the Issuer's Series A Cumulative Perpetual Preferred Stock, par value $0.001 per share. Sales under the plan were permitted to begin on October 1, 2026, and the plan expires on October 1, 2028, unless terminated earlier.

F2: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.11 on October 14, 2026, $9.06 to $9.60 on October 15, 2026, and $9.16 to $9.24 on October 16, 2026. The Reporting Person undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price such shares were sold.

F3: Includes 6,257 shares of restricted stock credited to the Reporting Person's account under the Issuer's 2009 Incentive Stock and Awards Plan, as amended and restated. Mr. Eberwein has elected to receive fifty percent of his base salary in the form of such restricted stock. Each share of restricted stock shall vest upon the first anniversary of the grant date and represents the right to receive, at settlement, one share of common stock.

F4: Includes (i) 23,852 shares of restricted stock and (ii) 6,750 RSUs credited to the Reporting Person's account under the Issuer's 2009 Incentive Stock and Awards Plan, as amended and restated; and (iii) 1,106,757 shares of common stock. Excludes 2,000 shares indirectly owned in contributory 401(k) and IRA accounts. Each share of restricted stock and each RSU represents the right to receive, at settlement, one share of common stock.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.

F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $45.075 to $46.065 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $46.08 to $47.07 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $47.075 to $48.07 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $48.08 to $48.15 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $47.14 to $47.89 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Each share of Class B Common Stock held by the Reporting Person will automatically convert into one share of Class A Common Stock upon the sale or transfer of such share of Class B Common Stock, subject to certain exceptions, and in certain other circumstances described in the Issuer's amended and restated certificate of incorporation. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock. The Class B Common Stock has no expiration.

F2: Includes shares issuable on settlement of restricted stock units.

F3: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2026, and occurred pursuant to the pre-established terms of such plan rather than as a result of a discretionary decision by the Reporting Person to sell shares at that time.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.34 to $39.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.36 to $39.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.04 to $38.035 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.04 to $38.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.065 to $39.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.205 to $38.195 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.21 to $38.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F11: The shares are held by the Colis Zhan Family Trust (the "Trust"). The Reporting Person is a trustee of the Trust.

F12: Shares held by John N. Colis, not individually, but solely as Trustee of the Peter G. Colis Family Trust U/A/D 7/4/2021.

F13: Shares held by Cresset Trust Company, a South Dakota-charted public trust company solely as Trustee of the PGC Beta Trust U/A/D 10/18/2024.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Each share of Class B Common Stock held by the Reporting Person will automatically convert into one share of Class A Common Stock upon the sale or transfer of such share of Class B Common Stock, subject to certain exceptions, and in certain other circumstances described in the Issuer's amended and restated certificate of incorporation. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock. The Class B Common Stock has no expiration.

F2: Includes shares issuable on settlement of restricted stock units.

F3: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2026, and occurred pursuant to the pre-established terms of such plan rather than as a result of a discretionary decision by the Reporting Person to sell shares at that time.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.34 to $39.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.36 to $39.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.04 to $38.035 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.04 to $38.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.065 to $39.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.205 to $38.195 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.21 to $38.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F11: The shares are held by the Colis Zhan Family Trust (the "Trust"). The Reporting Person is a trustee of the Trust.

F12: Shares held by John N. Colis, not individually, but solely as Trustee of the Peter G. Colis Family Trust U/A/D 7/4/2021.

F13: Shares held by Cresset Trust Company, a South Dakota-charted public trust company solely as Trustee of the PGC Beta Trust U/A/D 10/18/2024.

price is weighted average

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Purchase of shares through the Dividend Reinvestment and Stock Purchase Plan on 10/15/2026.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Purchase of shares through the Dividend Reinvestment and Stock Purchase Plan on 10/15/2026.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted on 3/16/2026 by the Reporting Person.

F2: These options vested at a rate of 1/48th per month starting on March 25, 2021.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into in good faith by the Reporting Person on April 7, 2026 for investment diversification purposes.

F2: Includes 6,442.63 restricted stock units which are subject to certain vesting and forfeiture provisions.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Sale of shares pursuant to a Rule 10b5-1 trading plan adopted by the D&E Living Trust and the EFS 2020 Irrevocable Trust on February 19, 2026.

F2: Shares held directly by the D&E Living Trust. The Reporting Person and David Siminoff serve as co-trustees and retain voting and dispositive power with respect to the shares held by the D&E Living Trust.

F3: Shares held directly by the EFS 2020 Irrevocable Trust. The Reporting Person serves as trustee and holds voting and dispositive power with respect to these shares.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: Sale of shares pursuant to a Rule 10b5-1 trading plan adopted by the D&E Living Trust and the EFS 2020 Irrevocable Trust on February 19, 2026.

F2: Shares held directly by the D&E Living Trust. The Reporting Person and David Siminoff serve as co-trustees and retain voting and dispositive power with respect to the shares held by the D&E Living Trust.

F3: Shares held directly by the EFS 2020 Irrevocable Trust. The Reporting Person serves as trustee and holds voting and dispositive power with respect to these shares.

Footnotes belong to the filing; numbered references identify the affected fields. They are not automatically assigned to every row.

F1: The shares of Common Stock were acquired pursuant to the Kingsway America Inc. Employee Share Purchase Plan, as amended and restated effective May 29, 2014 (the "ESPP"). Pursuant to the ESPP, eligible employees may contribute an amount up to 5% of adjusted salary for each regular payroll period and, to the extent such employee has been employed by Kingsway America Inc. and its subsidiaries for 12 months, the company will make a matching contribution equal to 100% of such employee's contribution. The employee contributions and company contributions are used to purchase, as soon as administratively practicable after the date of such contributions, shares of Kingsway Corporation The shares are acquired by the administrator of the ESPP on the open market through the services of a duly registered stockbroker.

F2: Includes 300,000 shares of restricted stock granted on March 31, 2021.